Polygenic risk scores of several subtypes of epilepsies in a founder population

被引:15
|
作者
Moreau, Claudia [1 ]
Rebillard, Rose-Marie [2 ]
Wolking, Stefan [2 ]
Michaud, Jacques [3 ]
Tremblay, Frederique [1 ]
Girard, Alexandre [1 ]
Bouchard, Joanie [1 ]
Minassian, Berge [4 ]
Laprise, Catherine [1 ]
Cossette, Patrick [2 ]
Girard, Simon L. [1 ]
机构
[1] Univ Quebec A Chicoutimi, Ctr Intersectoriel Sante Durable, Saguenay, PQ, Canada
[2] Univ Montreal, Axe Neurosci, Ctr Rech, Montreal, PQ, Canada
[3] Univ Montreal, Ctr Rech, CHU Ste Justine, Montreal, PQ, Canada
[4] UT SouthWestern Med Ctr, Dept Pediat & Neurol & Neurotherapeut, Dallas, TX USA
关键词
GENETICS;
D O I
10.1212/NXG.0000000000000416
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
ObjectivePolygenic risk scores (PRSs) are used to quantify the cumulative effects of a number of genetic variants, which may individually have a very small effect on susceptibility to a disease; we used PRSs to better understand the genetic contribution to common epilepsy and its subtypes.MethodsWe first replicated previous single associations using 373 unrelated patients. We then calculated PRSs in the same French Canadian patients with epilepsy divided into 7 epilepsy subtypes and population-based controls. We fitted a logistic mixed model to calculate the variance explained by the PRS using pseudo-R-2 statistics.ResultsWe show that the PRS explains more of the variance in idiopathic generalized epilepsy than in patients with nonacquired focal epilepsy. We also demonstrate that the variance explained is different within each epilepsy subtype.ConclusionsGlobally, we support the notion that PRSs provide a reliable measure to rightfully estimate the contribution of genetic factors to the pathophysiologic mechanism of epilepsies, but further studies are needed on PRSs before they can be used clinically.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] How reliable are polygenic risk scores for risk prediction in patients with heart disease?
    Jacob, Erin O.
    Hegele, Robert A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2023, 23 (02) : 105 - 107
  • [22] Improving the Utility of Polygenic Risk Scores as a Biomarker for Alzheimer's Disease
    Vlachakis, Dimitrios
    Papakonstantinou, Eleni
    Sagar, Ram
    Bacopoulou, Flora
    Exarchos, Themis
    Kourouthanassis, Panos
    Karyotis, Vasileios
    Vlamos, Panayiotis
    Lyketsos, Constantine
    Avramopoulos, Dimitrios
    Mahairaki, Vasiliki
    CELLS, 2021, 10 (07)
  • [23] Risk Prediction Using Polygenic Risk Scores for Prevention of Stroke and Other Cardiovascular Diseases
    Abraham, Gad
    Rutten-Jacobs, Loes
    Inouye, Michael
    STROKE, 2021, 52 (09) : 2983 - 2991
  • [24] Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease
    Schunkert, Heribert
    Di Angelantonio, Emanuele
    Inouye, Michael
    Patel, Riyaz S.
    Ripatti, Samuli
    Widen, Elisabeth
    Sanderson, Saskia C.
    Kaski, Juan Pablo
    Mcevoy, John W.
    Vardas, Panos
    Wood, Angela
    Aboyans, Victor
    Vassiliou, Vassilios S.
    Visseren, Frank L. J.
    Lopes, Luis R.
    Elliott, Perry
    Kavousi, Maryam
    EUROPEAN HEART JOURNAL, 2025,
  • [25] Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings
    Zheng, Sean L.
    Jurgens, Sean J.
    Mcgurk, Kathryn A.
    Xu, Xiao
    Grace, Chris
    Theotokis, Pantazis I.
    Buchan, Rachel J.
    Francis, Catherine
    de Marvao, Antonio
    Curran, Lara
    Bai, Wenjia
    Pua, Chee Jian
    Tang, Hak Chiaw
    Jorda, Paloma
    van Slegtenhorst, Marjon A.
    Verhagen, Judith M. A.
    Harper, Andrew R.
    Ormondroyd, Elizabeth
    Chin, Calvin W. L.
    Pantazis, Antonis
    Baksi, John
    Halliday, Brian P.
    Matthews, Paul
    Pinto, Yigal M.
    Walsh, Roddy
    Amin, Ahmad S.
    Wilde, Arthur A. M.
    Cook, Stuart A.
    Prasad, Sanjay K.
    Barton, Paul J. R.
    O'Regan, Declan P.
    Lumbers, R. T.
    Goel, Anuj
    Tadros, Rafik
    Michels, Michelle
    Watkins, Hugh
    Bezzina, Connie R.
    Ware, James S.
    NATURE GENETICS, 2025, : 563 - 571
  • [26] Attention-Deficit/Hyperactivity Disorder Polygenic Risk Scores Predict Attention Problems in a Population-Based Sample of Children
    Groen-Blokhuis, Maria M.
    Middeldorp, Christel M.
    Kan, Kees-Jan
    Abdellaoui, Abdel
    van Beijsterveldt, Catharina E. M.
    Ehli, Erik A.
    Davies, Gareth E.
    Scheet, Paul A.
    Xiao, Xiangjun
    Hudziak, James J.
    Hottenga, Jouke-Jan
    Neale, Ben M.
    Boomsma, Dorret I.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2014, 53 (10) : 1123 - 1129
  • [27] Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants
    Choi, Jungyoon
    Jia, Guochong
    Wen, Wanqing
    Long, Jirong
    Zheng, Wei
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (12) : 3416 - 3423
  • [28] Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs
    Delacretaza, Aurelie
    Santos, Patricia Lagares
    Morgui, Nuria Saigi
    Vandenberghe, Frederik
    Glatard, Anais
    Gholam-Rezaee, Mehdi
    von Gunten, Armin
    Conus, Philippe
    Eap, Chin B.
    PHARMACOGENETICS AND GENOMICS, 2017, 27 (12) : 464 - 472
  • [29] The utility of obesity polygenic risk scores from research to clinical practice: A review
    Jansen, Philip R.
    Vos, Niels
    van Uhm, Jorrit
    Dekkers, Ilona A.
    van Der Meer, Rieneke
    Mannens, Marcel M. A. M.
    van Haelst, Mieke M.
    OBESITY REVIEWS, 2024, 25 (11)
  • [30] Polygenic risk scores for predicting outcomes and treatment response in psychiatry: hope or hype?
    Fusar-Poli, Laura
    Rutten, Bart P. F.
    van Os, Jim
    Aguglia, Eugenio
    Guloksuz, Sinan
    INTERNATIONAL REVIEW OF PSYCHIATRY, 2022, 34 (7-8) : 663 - 675